By Professor Ric Day

Journal articles

Lu CY; Macneill P; Williams K; Day R, 2008, 'Access to high cost medicines in Australia: Ethical perspectives', Australia and New Zealand Health Policy, 5, http://dx.doi.org/10.1186/1743-8462-5-4

Lee M; Graham GG; Williams KM; Day RO, 2008, 'A benefit-risk assessment of benzbromarone in the treatment of gout - was its withdrawal from the market in the best interest of patients?', Drug Safety, 31, pp. 643 - 665

Lu CY; Williams KM; Day RO, 2008, 'Access to biologic medicines for the treatment of rheumatic diseases: lessons from Australia', International Journal of Rheumatology, 11, pp. 11 - 14

Xu H; Liauw WS; Murray M; Day RO; Mclachlan AJ, 2008, 'Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide', British Journal of Pharmacology, 153, pp. 1579 - 1586, http://dx.doi.org/10.1038/sj.bjp.0707685

Magrabi F; Westbrook JI; Kidd MR; Day RO; Coiera E, 2008, 'Long-term patterns of online evidence retrieval use in general practice: A 12-month study', Journal of Medical Internet Research, 10

McLachlan AJ; Day RO; Williams KM; Graham GG, 2008, 'Maximising gout therapy', Australian Journal of Pharmacy, 89, pp. 86 - 88

Chung Y; Stocker S; Graham GG; Day RO, 2008, 'Optimizing therapy with allopurinol: Factors limiting hypouricemic efficacy', American Journal of the Medical Sciences, 335, pp. 219 - 226

Abdul M; Jiang XM; Day RO; Roufogalis B; Liauw WS; Xu H; Mclachlan AJ, 2008, 'Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects', British Journal of Pharmacology, 154, pp. 1691 - 1700

Stocker S; Williams KM; Mclachlan AJ; Graham GG; Day RO, 2008, 'Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects', Clinical Pharmacokinetics, 47, pp. 111 - 118

Chung YW; Lu CY; Graham GG; Mant A; Day RO, 2008, 'Utilization of allopurinol in the Australian community', Internal Medicine Journal, 38, pp. 388 - 395

Kaye K; Lu C; Day R, 2007, 'Can we deny patients expensive drugs? [2]', Australian Prescriber, 30, pp. 60

Graham GG; Day RO, 2007, 'Expert comment [6]', Australian Prescriber, 30, pp. 61 - 62

Graham GG; Day RO, 2007, 'Paracetamol comment', AUSTRALIAN PRESCRIBER, 30, pp. 61 - 62, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000434589000006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Murnion BP; Granot R; Day RO, 2007, 'Utility of urine drug screening: A clinical audit', EMA - Emergency Medicine Australasia, 19, pp. 246 - 252, http://dx.doi.org/10.1111/j.1742-6723.2007.00922.x

Lu CY; Williams KM; Day RO, 2007, 'The funding and use of high-cost medicines in Australia: The example of anti-rheumatic biological medicines', Australia and New Zealand Health Policy, 4, http://dx.doi.org/10.1186/1743-8462-4-2

Day RO; Graham G; Williams K, 2007, 'Fenofibratewarfarin interaction [1]', Australian Prescriber, 30, pp. 32, http://dx.doi.org/10.18773/austprescr.2007.014

Day R; Lu CY; Pearce G; Grainger D, 2007, 'Pharmaceutical benefits scheme: Rapid change and impetus towards achieving QUM', Journal of Pharmacy Practice and Research, 37, pp. 4 - 6, http://dx.doi.org/10.1002/j.2055-2335.2007.tb00644.x

Granot R; Day RO; Cohen ML; Murnion B; Garrick R, 2007, 'Targeted pharmacotherapy of evoked phenomena in neuropathic pain: A review of the current evidence', Pain Medicine, 8, pp. 48 - 64, http://dx.doi.org/10.1111/j.1526-4637.2007.00156.x

Granot R; Day RO; Cohen ML; Murnion B; Garrick R, 2007, '639: Targeted pharmacotherapy of evoked phenomena in neuropathic pain', Journal of Clinical Neuroscience, 14, pp. 1031 - 1031, http://dx.doi.org/10.1016/j.jocn.2007.02.070

Hancock M; Maher CG; Latimer J; Mclachlan AJ; Cooper C; Day RO; Spindler M; McAuley J, 2007, 'Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first-line treatment for acute low back pain: a randomised controlled trial', Lancet, 370, pp. 1638 - 1643

Day RO; Graham GG; Hicks M; Mclachlan AJ; Stocker S; Williams KM, 2007, 'Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol', Clinical Pharmacokinetics, 46, pp. 623 - 644

Kelman CW; Pearson S; Day RO; D Arcy C; Holman JW; Kliewer E; Henry D, 2007, 'Evaluating medicines: let`s use all the evidence', Medical Journal of Australia, 186, pp. 249 - 252

Lu CY; Williams KM; Day RO, 2007, 'Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?', Internal Medicine Journal, 37, pp. 601 - 606, http://dx.doi.org/10.1111/j.1445-5994.2007.01396.x

Mikhail S; Zwar NA; Vagholkar S; Dennis SM; Day RO, 2007, 'Non-steroidal anti-inflammatory drugs in general practice: a decision-making dilemma', Medical Journal of Australia, 187, pp. 160 - 163

Day RO; Williams KM, 2007, 'Open-label extension studies - Do they provide meaningful information on the safety of new drugs?', Drug Safety, 30, pp. 93 - 105

Pearson S; Ringland C; Kelman CW; Mant A; Lowinger J; Stark H; Nichol G; Day RO; Henry DA, 2007, 'Patterns of analgesic and anti-inflammatory medicine use by Australian veterans', Internal Medicine Journal, 37, pp. 798 - 805

Tan E; Day RO; Brien JE, 2007, 'Prioritising drug and therapeutics committee (DTC) decisions: a national survey', Pharmacy World and Science, 29, pp. 90 - 96

Miners JO; Day RO, 2007, 'Relationships between the adverse effects of drugs and genetic polymorphism in genes encoding drug metabolizing enzymes', British Journal of Clinical Pharmacology, 63, pp. 380 - 381

Lu C; Ritchie JE; Williams KM; Day RO, 2007, 'The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia', Australia and New Zealand Health Policy, 4

McNeill PM; Kerridge IH; Arciuli C; Henry DA; Macdonald GJ; Day RO; Hill SR, 2006, 'Gifts, Drug Samples, and other Items Given to Medical Specialists by Pharmaceutical Companies', Journal of Bioethical Inquiry, 3, pp. 139 - 148, http://dx.doi.org/10.1007/s11673-006-9019-0

Reicin A; Shapiro D, 2006, 'Response to expression of concern regarding VIGOR study.', N Engl J Med, 354, pp. 1196 - 1199, https://www.ncbi.nlm.nih.gov/pubmed/16544387

Kaye KI; Welch SA; Graudins LV; Graudins A; Rotem T; Davis SR; Day RO, 2006, 'In reply [9]', Medical Journal of Australia, 184, pp. 44 - 45, http://dx.doi.org/10.5694/j.1326-5377.2006.tb00101.x

Kaye KI; Lu CY; Day RO, 2006, 'Can we deny patients expensive drugs?', Australian Prescriber, 29, pp. 146 - 148, http://dx.doi.org/10.18773/austprescr.2006.087

Lu CY; Williams KM; Day RO, 2006, 'Access to high-cost medicines for the treatment of rheumatoid arthritis under Australia's pharmaceutical benefits scheme', Pharmacoepidemiology and Drug Safety, 15, pp. S213 - S213

Lu CY; Williams KM; Day RO, 2006, 'Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target?', Internal Medicine Journal, 36, pp. 19 - 27, http://dx.doi.org/10.1111/j.1445-5994.2005.00992.x

Lu CY; Williams KM; Day RO, 2006, 'Accessing health outcome data on high-cost medicines in Australia', Medical Journal of Australia, 184, pp. 411 - 413, http://dx.doi.org/10.5694/j.1326-5377.2006.tb00293.x

Strand V; Conaghan P; Lohmander L; Koutsoukos A; Hurley F; Bird H; Brooks PM; Day RO; Puhl W; Band P, 2006, 'An integrated analysis of five double-blind, randomized controlled trials evaluating the safety and efficacy of a hyaluronan product for intra-articular injection in osteoarthritis of the kneel', Osteoarthritis and Cartilage, 14, pp. 859 - 866

Loboz K; Gross AS; Williams KM; Liauw WS; Day RO; Blievernicht J; Zanger U; McLachlan AJ, 2006, 'Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: Effect of induction by rifampin and ethnicity', Clinical Pharmacology and Therapeutics, 80, pp. 75 - 84

Mcneill PM; Kerridge IH; Henry DA; Stokes B; Hill SR; Newby D; Macdonald GJ; Day RO; Maguire J; Henderson KM, 2006, 'Giving and receiving of gifts between pharmaceutical companies and medical specialists in Australia', Internal Medicine Journal, 26, pp. 571 - 578

Kaye KI; Welch SA; Graudins LV; Graudins A; Rotem T; Davis SR; Day RO, 2006, 'Pethidine in emergency departments: promoting evidence-based prescribing - Reply', Medical Journal of Australia, 184, pp. 44 - 45

Coiera E; Magrabi F; Westbrook JI; Kidd MR; Day RO, 2006, 'Protocol for the Quick Clinical study - a randomised controlled trial to assess the impact of an online evidence retrieval system on decision-making in general practice', BMC Medical Informatics and Decision Making, 6

Bombardier C; Laine L; Burgos-Vargas R; Davis BE; Day RO; Ferraz MB; Hawkey CJ; Hochberg MC; Kvien T; Schnitzer TJ; Weaver AJ; Reicin A; Shapiro D, 2006, 'Response to expression of concern regarding VIGOR study', New England Journal of Medicine, 354, pp. 1196 - 1198

Lu CY; Williams KM; Day RO, 2006, 'Utilisation of anti-rheumatic drugs in Australia: Impact of introducing high-cost biologics under the pharmaceutical benefits scheme', Pharmacoepidemiology and Drug Safety, 15, pp. S213 - S213

Tan EL; Day RO; Brien JAE, 2005, 'Perspectives on Drug and Therapeutics Committee policy implementation', Research in Social and Administrative Pharmacy, 1, pp. 526 - 545, http://dx.doi.org/10.1016/j.sapharm.2005.09.001

Lu CY; Williams K; Day R, 2005, 'Evaluation of access to high-cost medicines in Australia using national claims data', VALUE IN HEALTH, 8, pp. A28 - A28, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000233021700088&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Day RO; Birkett DJ; Miners J; Shenfield GM; Henry DA; Seale JP, 2005, 'Access to medicines and high-quality therapeutics: Global responsibilities for clinical pharmacology', Medical Journal of Australia, 182, pp. 322 - 323, http://dx.doi.org/10.5694/j.1326-5377.2005.tb06728.x

Day R; Adams S, 2005, 'The birth of ibuprofen', Australian Journal of Pharmacy, 86, pp. 84 - 85

Lassere MN; Johnson KR; Woodworth G; Furst DE; Fries J; Kirwan J; Tugwell P; Day RO; Brooks P, 2005, 'Challenges and Progress in adverse event ascertainment and reporting in clinical trials', Journal of Rheumatology, 32, pp. 2030 - 2032

Kerridge IH; Maguire J; Newby D; Mcneill PM; Henry D; Hill SB; Day RO; Macdonald GJ; Stokes B; Henderson K, 2005, 'Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations', Internal Medicine Journal, 35, pp. 206 - 210

Jiang X; Williams KM; Liauw WS; Ammit A; Roufogalis B; Duke C; Day RO; McLachlan AJ, 2005, 'Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects', British Journal of Clinical Pharmacology, 59, pp. 425 - 432

Back to profile page